Apixaban was also more clinically effective than dabigatran etexilate and enoxaparin. Both apixaban and rivaroxaban dominated dabigatran etexilate and enoxaparin in the analyses for total knee ...

Apixaban is recommended as an option for preventing stroke and systemic embolism within its marketing authorisation, that is, in people with non-valvular atrial fibrillation with 1 or more risk ...

Apixaban is an oral anticoagulant that inhibits factor Xa. It is one of a clutch of new oral agents competing with warfarin as a first line treatment for people with atrial fibrillation. Drug trials ...

Apixaban dose was adjusted to 2.5 mg twice daily for subjects with any two of the following: age ≥80 years, body weight ≤60 kg, and serum creatinine ≥1.5 mg/dl. Outcomes and treatment effect were ...

Apixaban would still cost patients 9 times more through the Eliquis 360 Support program than with commercial insurance.

Methods and analysis This Australian multicentre RCT will compare 2.5 mg apixaban with placebo, in parallel treatment groups randomised in a 1:1 ratio, both administered twice daily for 3 years as ...

For research papers The BMJ has fully open peer review. This means that accepted research papers published from early 2015 onwards usually have their prepublication history posted alongside them on ...

Eliquis (apixaban) is an oral selective Factor Xa inhibitor. By inhibiting Factor Xa, a key blood clotting protein, Eliquis decreases thrombin generation and blood clot formation.

Costs for several medicines have surged in recent weeks including the price of the commonly prescribed drug Apixaban – used to prevent blood clots – which now costs £36 per pack.

The RENAL-AF trial (Renal Hemodialysis Patients Allocated Apixaban Versus Warfarin in Atrial Fibrillation) was a prospective, randomized, open-label, blinded-outcome evaluation (PROBE) of apixaban ...